Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 36, 2014, Pages 13151-13156

  Chun, Tae Wook ^a   Murray, Danielle ^a   Justement, Jesse S ^a   Blazkova, Jana ^a   Hallahan, Claire W ^b   Fankuchen, Olivia ^a   Gittens, Kathleen ^a   Benko, Erika ^c   Kovacs, Colin ^c,d   Moir, Susan ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Maple Leaf Medical   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

HIV envelope protein; HIV specific antibodies; Latent HIV

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

CD4+ T LYMPHOCYTE; DISEASE CARRIER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; SPECIES DIFFERENCE; VIREMIA; VIRION; VIROLOGY; VIRUS REPLICATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; SPECIES SPECIFICITY; VIREMIA; VIRION; VIRUS REPLICATION;

EID: 84906968862     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414148111     Document Type: Article

References (25)

1. Chun TW, Fauci AS (2012) HIV reservoirs: Pathogenesis and obstacles to viral eradication and cure. AIDS 26(10):1261-1268.
2. Burton DR, et al. (2012) A blueprint for HIV vaccine discovery. Cell Host Microbe 12(4):396-407.
3. Fauci AS, Marston HD (2014) Ending AIDS - is an HIV vaccine necessary? N Engl J Med 370(6):495-498.
4. Moir S, Malaspina A, Fauci AS (2011) Prospects for an HIV vaccine: Leading B cells down the right path. Nat Struct Mol Biol 18(12):1317-1321.
5. Kwong PD, Mascola JR (2012) Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 37(3):412-425.
6. Zhou T, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329(5993):811-817.
7. Walker LM, et al.; Protocol G Principal Investigators (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470.
8. Mascola JR, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6(2):207-210.
9. Nishimura Y, et al. (2003) Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 100(25):15131-15136.
10. Trkola A, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11(6):615-622.
11. Klein F, et al. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118-122.
12. Shingai M, et al. (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503(7475):277-280.
13. Barouch DH, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503(7475):224-228.
14. Horwitz JA, et al. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 110(41):16538-16543.
15. Malbec M, et al. (2013) Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 210(13):2813-2821.
16. Chun TW, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94(24):13193- 13197.
17. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341):1295-1300.
18. Wong JK, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278(5341):1291-1295.
19. Davey RT, Jr, et al. (1999) HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96(26):15109-15114.
20. Deeks SG, et al.; International AIDS Society Scientific Working Group on HIV Cure (2012) Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 12(8):607-614.
21. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20(4):425-429.
22. Kwong PD, Mascola JR, Nabel GJ (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13(9):693-701.
23. Pancera M, et al. (2013) Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 20(7):804-813.
24. Bonomelli C, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 6(8):e23521.
25. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5):343-357.